Ubs Asset Management Americas Inc Viridian Therapeutics, Inc.\De Transaction History
Ubs Asset Management Americas Inc
- $277 Billion
- Q1 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 28,309 shares of VRDN stock, worth $344,237. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,309
Previous 15,161
86.72%
Holding current value
$344,237
Previous $330,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding VRDN
# of Institutions
143Shares Held
62.1MCall Options Held
160KPut Options Held
354K-
Paradigm Biocapital Advisors LP New York, NY5.03MShares$61.2 Million3.3% of portfolio
-
State Street Corp Boston, MA4.49MShares$54.6 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$47.2 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.81MShares$46.4 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.66MShares$44.5 Million1.34% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $485M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...